» Articles » PMID: 39132058

Iberogast®-Induced Acute Liver Injury-A Case Report

Overview
Journal Gastro Hep Adv
Specialty Gastroenterology
Date 2024 Aug 12
PMID 39132058
Authors
Affiliations
Soon will be listed here.
Abstract

Alternative medicines such as phytotherapy and herbal preparations have been widely used over the past 5 decades. However, they are still poorly known in Western medicine, and because they are considered as natural products, they are often omitted in the review of medication. One of the most used herbal preparations in Europe is Iberogast®, a formulation of 9 medicinal plant extracts, including Greater Celandine that has proven effective in the treatment of functional dyspepsia and irritable bowel syndrome. Safety and tolerability of Iberogast® were extensively evaluated in double-blind and randomized studies vs placebo, but rare and usually mild adverse symptoms have been reported in the literature. We report a 32-year-old female with no previous medical history who presented to the emergency department with abdominal pain, jaundice, and pruritus. The blood tests revealed an acute severe hepatitis with marked increase of direct bilirubin. After exclusion of other possible acute liver injury etiologies, we retained the diagnosis of Iberogast®-associated drug-induced liver injury. Patient's symptoms resolved spontaneously 5 weeks after treatment interruption. Despite the general safety of Iberogast®, occasional cases of drug-induced liver injury have been documented. Based on these observations, we recommend that the use of herbal and phytotherapeutic products should be part of the standard investigation of the medical history, as they could be relevant information in the diagnosis process of acute liver injury.

Citing Articles

Herbal Approaches to Pediatric Functional Abdominal Pain.

Cherry R, Blanchard S, Chogle A, Santucci N, Mehta K, Russell A Children (Basel). 2022; 9(8).

PMID: 36010156 PMC: 9406842. DOI: 10.3390/children9081266.

References
1.
European Association For The Study Of The Liver . Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series [J Hepatol 73 (2020) 1170-1218]. J Hepatol. 2022; 78(2):452. DOI: 10.1016/j.jhep.2022.10.006. View

2.
Bull L, Van Eijk M, Pawlikowska L, DeYoung J, Juijn J, Liao M . A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet. 1998; 18(3):219-24. DOI: 10.1038/ng0398-219. View

3.
Ottillinger B, Storr M, Malfertheiner P, Allescher H . STW 5 (Iberogast®)--a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr. 2012; 163(3-4):65-72. PMC: 3580135. DOI: 10.1007/s10354-012-0169-x. View

4.
Gomez-Ospina N, Potter C, Xiao R, Manickam K, Kim M, Kim K . Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. Nat Commun. 2016; 7:10713. PMC: 4759630. DOI: 10.1038/ncomms10713. View

5.
Andrade R, Lucena M, Fernandez M, Pelaez G, Pachkoria K, Garcia-Ruiz E . Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005; 129(2):512-21. DOI: 10.1016/j.gastro.2005.05.006. View